Early results suggest that SARS-CoV-2 vaccines are highly effective for the prevention of COVID-19. Unfortunately, until we can safely, rapidly, and affordably vaccinate enough people to achieve collective immunity, we cannot afford to disregard the benefits of naturally acquired immunity in those, whose prior documented infections have already run their course. As long as the vaccine manufacturing, supply, or administration are limited in capacity, vaccination of individuals with naturally acquired immunity at the expense of others without any immune protection is inherently inequitable, and violates the principle of justice in biomedical ethics. Any preventable disease acquired during the period of such unnecessary delay in vaccination should not be overlooked, as it may and will result in some additional morbidity, mortality, related hospitalizations, and expense. Low vaccine production capacity complicated by inefficiencies in vaccine administration suggests, that vaccinating preferentially those without any prior protection will result in fewer natural infections more rapidly.

中文翻译：

---

COVID-19 和 SARS-CoV-2 疫苗接种后的感染后免疫


早期结果表明 SARS-CoV-2 疫苗对于预防 COVID-19 非常有效。不幸的是，在我们能够安全、快速、经济地为足够多的人接种疫苗以实现集体免疫之前，我们不能忽视那些先前记录的感染已经结束的人自然获得的免疫力的好处。只要疫苗的生产、供应或管理能力有限，以牺牲没有任何免疫保护的其他人为代价来为具有天然免疫力的个体接种疫苗，本质上就是不公平的，也违反了生物医学伦理学的正义原则。在这种不必要的疫苗接种延迟期间获得的任何可预防的疾病都不应被忽视，因为它可能并且将会导致一些额外的发病率、死亡率、相关的住院治疗和费用。疫苗生产能力低下加上疫苗管理效率低下表明，优先为那些没有任何事先保护的人接种疫苗将更快地减少自然感染。